(Q42261957)

19 October 2017

Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome (English)

1 reference

19 October 2017

1 reference

1 reference

4

1 reference

Anne-Laure Sellier-Leclerc

19 October 2017

1

object named as

Anne-Laure Sellier-Leclerc

0 references

Georges Deschênes

5

object named as

Georges Deschênes

0 references

author name string

Anne-Laure Sellier-Leclerc

1

1 reference

19 October 2017

Emre Belli

2

1 reference

19 October 2017

Valérie Guérin

3

1 reference

19 October 2017

Georges Deschênes

5

1 reference

19 October 2017

23 May 2013

1 reference

19 October 2017

1 reference

19 October 2017

28

1 reference

19 October 2017

9

1 reference

19 October 2017

1875-1879

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-013-2485-9

19 October 2017

0 references

cites work

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Rituximab in refractory nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Fatal pulmonary fibrosis after rituximab administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Severe ulcerative colitis after rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2485-9

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

21 January 2018

1 reference

12 December 2020

Rituximab efficiency in children with steroid-dependent nephrotic syndrome

1 reference

12 December 2020

Severe respiratory adverse events associated with rituximab infusion

1 reference

12 December 2020

Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome

1 reference

12 December 2020

1 reference

12 December 2020

Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

1 reference

12 December 2020

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

12 December 2020

Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases

1 reference

12 December 2020

Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery

1 reference

12 December 2020

10.1007/S00467-013-2485-9

Identifiers

DOI

1 reference

Dimensions Publication ID

19 October 2017

0 references

1 reference